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Abstract
Objective: To elucidate the anti-inflammatory and anabolic effects of regulated expression of IL-4 in chondrocyte-scaffolds
under in vitro inflammatory conditions.
Methods: Mature articular chondrocytes from dogs (n=3) were conditioned through transient transfection using
pcDNA3.1.cIL-4 (constitutive) or pCOX-2.cIL-4 (cytokine-responsive) plasmids. Conditioned cells were seeded in alginate
microspheres and rat-tail collagen type I matrix (CaReSH) to generate two types of tissue-engineered 3-dimensional
scaffolds. Inflammatory arthritis was simulated in the packed chondrocytes through exogenous addition of recombinant
canine (rc) IL-1b (100 ng/ml) plus rcTNFa (50 ng/ml) in culture media for 96 hours. Harvested cells and culture media were
analyzed by various assays to monitor the anti-inflammatory and regenerative (anabolic) properties of cIL-4.
Results: cIL-4 was expressed from COX-2 promoter exclusively on the addition of rcIL-1b and rcTNFa while its expression
from CMV promoter was constitutive. The expressed cIL-4 downregulated the mRNA expression of IL-1b, TNFa, IL-6, iNOS
and COX-2 in the cells and inhibited the production of NO and PGE2 in culture media. At the same time, it up-regulated the
expression of IGF-1, IL-1ra, COL2a1 and aggrecan in conditioned chondrocytes in both scaffolds along with a diminished
release of total collagen and sGAG into the culture media. An increased amount of cIL-4 protein was detected both in
chondrocyte cell lysate and in concentrated culture media. Neutralizing anti-cIL-4 antibody assay confirmed that the anti-
inflammatory and regenerative effects seen are exclusively driven by cIL-4. There was a restricted expression of IL-4 under
COX-2 promoter possibly due to negative feedback loop while it was over-expressed under CMV promoter (undesirable).
Furthermore, the anti-inflammatory /anabolic outcomes from both scaffolds were reproducible and the therapeutic effects
of cIL-4 were both scaffold- and promoter-independent.
Conclusions: Regulated expression of therapeutic candidate gene(s) coupled with suitable scaffold(s) could potentially
serve as a useful tissue-engineering tool to devise future treatment strategies for osteoarthritis.
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Introduction
Osteoarthritis (OA) is the most common musculoskeletal
disorder worldwide. It is the major cause of morbidity in
developed nations and has enormous social and economic
consequences. It is a slowly developing multifactorial disorder
frequently associated with inflammation and progressive cartilage
degeneration.
Progressive loss of cartilage in OA results from an imbalance of
anabolic and catabolic metabolisms [1,2] through a complex
interaction of mechanical and biochemical factors [3,4,5]. Among
the latter, a number of catabolic factors, including pro-inflamma-
tory cytokines and proteases have been demonstrated to play
major roles [1,6,7,8].
Typically, repair in adult articular cartilage is very slow or even
absent [9]. Cell based therapies using autologous mature
chondrocytes or pre-chondrogenic stem cells in biodegradable
polymeric tridimensional (3D) scaffolds when transplanted into
focal lesions could regenerate hyaline-like cartilage [10,11,12].
However, pro-inflammatory mediators present in the joint could
affect the transplanted chondrocytes, potentiating the need to
suppress inflammation [13].
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identified as necessary for reducing inflammation or promoting
regeneration, the most promising therapeutic agents are those that
modulate the activities of the pro-inflammatory cytokines
interleukin-1 beta (IL-1b) and tumor necrosis factor alpha (TNFa)
which are thought to be important mediators that drive the
pathophysiology of OA [8,14,15]. Several anti-inflammatory and
anabolic agents have been tested that suppress the production of
pro-inflammatory mediators [16,17]. Among these IL-4 [18], IL-
10 [19] and IL-13 [20] are of utmost significance in the context of
OA.
We are interested in IL-4 because it has advantages over IL-10
or IL-13. As such, IL-4 compared to IL-10, is more potent
inhibitor of IL-1b and only IL-4 (not IL-10) can induce the
production of IL-1ra [21]. Further, IL-4 can antagonize the effects
of TNF by inducing down-regulation and shedding of both forms
of TNF receptors while IL-13 cannot produce such effects [22]
and unlike IL-4, it does not appear to directly regulate the growth
of Th2-type cells [23].
In addition, previous work using IL-4 under the control of
constitutive [24] and responsive [25,26] promoters revealed
downregulation of various pro-inflammatory cytokines such as
IL-1b, TNFa, IL-6 and enzymes involved in the production of
inflammatory mediators such as inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2) and their end products
nitric oxide (NO) and prostaglandin E2 (PGE2), respectively.
According to Geurts and co-workers [25], IL-4 can protect
cartilage erosion in collagen-induced arthritis and strongly reduces
amounts of inflammatory cell influx.
Ideally, autologous chondrocyte transplantation (ACT) coupled
with bioactive factors i.e. conditioning of cells with therapeutic
transgenes may add regenerative and curing functions to the well-
established repair function of conventional ACT [27]. This
combination may be utilized to down-regulate inflammatory
products and help restore the intrinsic biological function of the
tissue. Thus, this approach would represent an interesting and
unique modification of chondrocyte-seeded scaffolds that may
substantiate future efforts to optimize ACT.
Our initial findings from alginate culture revealed a diminished
expression of the inflammatory cytokines and other mediators in
conditioned chondrocytes through cIL-4 production under both
CMV (cytomegalovirus) and COX-2 promoters. These results
were very promising and prompted us to test our hypothesis in rat-
tail collagen type I CaReSH matrices, which are a suitable means
to facilitate cell seeding of scaffolds for cartilage tissue engineering
applications. Clinical trials of CaReSH matrices have shown
promising results. It has been reported that patellofemoral
transplantation of CaReSH matrices for two years showed a
significant increase in International Knee Documentation Com-
mittee (IKDC) scores in 78.6% of patients [28]. It has been
recently reported that CaReSH transplantation resulted in
complete defects filling with superior quality repair tissue
compared to Hyalograft-C, a hyaluronic-based scaffold at 2 years
post-surgery [29].
We hypothesize that canine IL-4 (cIL-4) expression by
chondrocytes could be induced in both scaffolds and anticipate
that conditioned chondrocytes seeded in the 3D scaffolds will be
able to abate inflammatory mediators and help regenerate
cartilage simultaneously when implanted into the joint. As these
scaffolds contain the cells previously conditioned with cytokine-
responsive promoter that deliver the transgene only when the
promoter will be turned on in the presence of IL-1b and TNFa,
we are introducing a term for this kind of approach as Autologous
Conditioned Cell Therapy (ACCT) for future in vivo experiments.
Materials and Methods
Isolation and culture of chondrocytes
Allproceduresinthisstudy,withregardtosamplecollectionfrom
euthanized animals at Clinic of Small Animals, Freie Universita ¨t,
Berlin, Germany, were conducted by authorized veterinarians in
full agreement with the formal requirements as statedby the Animal
Protection Office. However, for our in vitro study on such materials
no approval was necessary because no direct contact with live
animals was involved at all.
Adult articular cartilage tissues were harvested under sterile
conditionsfromfemoralcondylesoffivecaninecadaverswithin24 h
post-euthanasia. Chondrocytes were isolated as previously described
[30]. Briefly, cartilage was diced into 2–3 mm
2 slices and digested in
spinner flasks using a cocktail of enzymes consisting of 1 U/ml
Collagenase P (Roche Diagnostics, Mannheim, Germany), 330 U/
ml Collagenase CLS II (Biochrom, Berlin, Germany) and 30 U/ml
Hyaluronidase (Roche Diagnostics, Mannheim, Germany) at 37uC
for16–18 h.Theresultingsuspensionwasfilteredthrougha100 mm
cell strainer and chondrocytes were collected by centrifugation at
400 g for 20 min. Cells were then re-suspended in Dulbecco’s
Modified Eagle Medium (DMEM; Biochrom, Berlin, Germany)
enriched with 10% heat inactivated fetal bovine serum (FBS;
Biochrom, Berlin, Germany) and 100 U/ml penicillin and 100 mg/
ml streptomycin (Pan Biotech, Aidenbach, Germany). Cells were
counted and assessed for viability using trypan blue exclusion and
plated in 75 cm
2 culture flasks at 3610
6 cells/flask in the above-
mentioned culture media and incubated at 37uCi n5 %C O 2.B a s e d
on good growth rate and phenotypic characteristics, cells from three
donors (n=3) at third sub-culture were used in this study.
Preparation of DNA
cIL-4 was cloned into the pcDNA3.1 vector downstream of the
constitutively expressing CMV promoter (pcDNA3.1.cIL-4) and
downstream of the cytokine-responsive COX-2 promoter (pCOX-
2.cIL-4; Accession No. EU249362; 21145 bp to +93 bp) by
standard recombinant DNA technology [26,31]. The activity of
promoters and functioning of cIL-4 in monolayer culture were
previously determined [26].
Conditioning of chondrocytes
Chondrocytes at passage 3, were made conditioned through
transient transfection using FuGENE 6 (Boehringer, Mannheim,
Germany) [32] because this method yields approximately 50%
transfection efficiency [26]. cIL-4 containing plasmids (pcDNA3.1-
cIL-4, pCOX-2.cIL-4) were employed at 8 mg concentration
(1 mg/ml) for individual transfection of 1610
6 cells in 10 cm cell
culture dishes. A ratio of 3:2 (FuGENE 6: DNA) was prepared in
serum-free medium and added drop wise to the cells. Cells were
maintained in DMEM plus 1% FBS and 1% penicillin/
streptomycin at 37uC with 5% CO2.
Encapsulation of chondrocytes in alginate microspheres
Chondrocytes were harvested 24 h post-transfection by trypsin-
ization, washed twice with phosphate-buffered saline (PBS) and
encapsulated in alginate microspheres [32]. In total, 10 micro-
spheres (5 microspheres/ml) for each sample were placed in
DMEM supplemented with 10% FBS and 1% penicillin/strepto-
mycin and incubated as above for 24 h to allow equilibration of
microspheres to culture.
Generation of CaReSH matrices
Rat-tail collagen-based matrices (CaReSH) were generated 24 h
post-transfection at Amedrix, Esslingen, Germany. Chondrocytes
IL-4 Expression in Chondrocyte-Scaffolds
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neutralizing solution(GNS) foreach matrixusing1.0610
4–1.5610
4
chondrocytes and mixed with 2.5 ml of collagen type I gel. The
GNS/chondrocyte composite was cast for each gel, which was then
allowed to polymerize at 37uC for 20 min to generate matrices. The
matrices were placed in DMEM/F12 medium (Bioconcept,
Allschwil, Switzerland) containing 10% FBS and 1% gentamicin
(Biochrom, Berlin, Germany) for 24 h before stimulation.
Simulation of inflammatory arthritis within scaffolds
After equilibration period was over, culture medium was
aspirated and scaffolds were washed twice with PBS. Now,
alginate beads were cultured in DMEM with 1% FBS while
CaReSH matrices were cultured in DMEM/F12 with 1% FBS.
Recombinant canine (rc) IL-1b and rcTNFa were used [33] to
stimulate the inflammatory cascade in chondrocytes within both
scaffolds at a concentration of 100 ng/ml and 50 ng/ml
respectively for 96 h with essential controls.
Neutralizing anti-cIL-4 antibody assay
To assess whether the anti-inflammatory and regulatory effects
in conditioned chondrocytes are caused by the expression of cIL-4,
neutralizing goat anti-canine-cIL-4 polyclonal antibody (AF754,
R&D Systems, Wiesbaden-Nordenstadt, Germany) was added at a
concentration of 5 mg/ml to the culture media of cells stimulated
with recombinant canine pro-inflammatory cytokines for 96 h.
Culture media were collected and subjected to the nitrite assay as
described below.
Retrieval of cells from scaffolds
Entrapped chondrocytes from alginate microspheres were re-
isolated by digesting individual microspheres in 100 mlo f5 5m M
sodium citrate and 90 mM NaCl (pH 6.8) solution for 20 min at
room temperature. Cells were released from CaReSH scaffolds by
chopping the scaffolds to the size of a pinhead and subsequent
incubation of the suspension with 1 ml (1.25 U) of Collagenase P
with an equal volume of PBS. Samples were then incubated at
37uC for 20 min during which time the minced fractions were
completely digested thereby releasing chondrocytes into the
solution. The suspended chondrocytes from snapped alginate
and CaReSH matrix solutions were pelleted and kept at 280uC
until analyzed.
RNA isolation and RT-PCR
Total RNA was extracted from chondrocytes using EURx
GeneMATRIX universal RNA purification kit (Roboklon, Berlin,
Germany) according to supplied protocol. The extracted RNA
dissolved in DEPC-treated water was quantified by Nanodrop
system (Peqlab, Erlangen, Germany) and treated with DNase I
(Fermentas, St. Leon-Rot, Germany). One microgram of total
RNA was used to synthesize first-strand cDNA using RevertAid
Moloney murine leukemia virus reverse transcriptase and
Table 1. Sequences and characteristics of the various oligonucleotide primers.
Gene symbol S/A Primer sequences (59–39) Location Size (bp)
NCBI
accession No.
IL-1b S AGTTGCAAGTCTCCCACCAG 149–169 177 DQ251036
A TATCCGCATCTGTTTTGCAG 325–345
TNFa S TCATCTTCTCGAACCCCAAG 235–255 157 NM_001003244
A ACCCATCTGACGGCACTATC 391–411
IL-6 S GGCTACTGCTTTCCCTACCC 108–128 198 NM_001003301
A TTTTCTGCCAGTGCCTCTTT 305–325
iNOS S GGAGGAGCAGCTACTGTTGG 1227–1246 178 AF068682
A GTCATGAGCAAAGGCACAGA 1385–1404
COX-2 S GCCTTACCCAGTTTGTGGAA 1239–1258 163 NM_001003354
A AGCCTAAAGCGTTTGCGATA 1382–1401
IL-4 S CTCACCTCCCAACTGATTCC 70–89 156 NM_001003159
A CTTGACAGTCAGCTCCATGC 206–225
IGF-1 S CAGCAGTCTTCCAACCCAAT 12–31 105 XM_848024
A CAAGCACAGTGCCAGGTAGA 98–117
IL-1ra S GAAGAGACCTTGCAGGATGC 87–106 226 AF216526
A CTGGAGCCTGGTCTCATCTC 312–331
COL1a1 S GAACCTGGCAAACAAGGTC 3017–3035 150 NM_001003090
A AGGAGAACCATCTCGTCCA 3148–3166
COL2a1 S GAAACTCTGCCACCCTGAAT 3878–3897 160 NM_001006951
A GCTGCTCCACCAGTTCTTCT 4018–4037
Aggrecan S CTATGAGGACGGCTTTCACC 573–592 194 U65989.2
A AGACCTCACCCTCCATCTCC 747–766
G3PDH S TAT TGT CGC CAT CAA TGA CC 81–100 195 NM_01003142
A TAC TCA GCA CCA GCA TCA CC 261–275
S=sense (forward); A=antisense (reverse); bp=base pairs.
doi:10.1371/journal.pone.0025749.t001
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60 min, according to manufacturer’s protocol.
Quantification of mRNA expression
mRNA expression of IL-1b, TNFa, IL-4, IL-6, iNOS, COX-2,
insulin-like growth factor-1 (IGF-1), IL-1 receptor antagonist (IL-
1ra), collagens (COL1a1, COL2a1) and aggrecan was quantified.
Subsequently, the samples were subjected to quantitative real-time
PCR (qRT-PCR) using an iCycler iQ-5 (Bio-Rad, Munich,
Germany).
Reactions in triplicates were carried out in 20 ml reaction
volume containing 10 ml of SensiMixPlus SYBR (Quantace,
Berlin, Germany) with fluorescein and 3 mM MgCl2. Primers
(Table-1) were used at 500 nM, the cDNA was added at a
concentration of 500 ng (1 mg/ml). The gene for glyceraldehyde 3-
phosphate dehydrogenase (G3PDH) acted as an endogenous
reference for normalization of fluorescence thresholds (Ct) values
of target genes.
cIL-4 enzyme linked immunosorbent assay (ELISA)
The supernatant was collected from cells 96 h post-stimulation
and cells were harvested by centrifugation and lysed using RIPA
(radioimmunoprecipitation assay) buffer containing 1% Triton X-
100, 1% deoxycholate, 0.1% SDS (sodium dodecyl sulfate), 0.15 M
NaCl, 20 mM Tris, 10 mM EDTA (ethylenediaminetetraacetic
acid), 10 mM iodoacetamide, 1 mM PMSF (phenylmethylsulfonyl
fluoride) supplemented with protease inhibitors (10 mg/ml each of
aprotinin, leupeptin, and pepstatin). Proteins present in the culture
media were precipitated with the chloroform: methanol method
[34]. Proteins present in lysates and in concentrated supernatants
were quantified by the bicinchoninic acid method (Bio-Rad,
Munich, Germany). To determine IL-4 protein, sandwich ELISA
was performed on cell lysates and culture media from both matrices
according to the previously established protocol [24]. Briefly, 96-
well flat-bottomed plate (Nunc, Roskilde, Denmark) was coated
with 200 ml/well of house-raised Rabbit polyclonal cIL-4 antibody
(1:1000) for 24 h at 4uC. After 3x washing with PBS, the plate was
blocked using 200 ml of 1% bovine serum albumin in PBS for 2 h at
room temperature followed by 3x washing with PBS. Undiluted
samples and serial dilutions of standard rcIL-4 were dispensed in
triplicates and incubated at room temperature for 90 min. Plate was
rinsed 3x with PBS-Tween (0.1% Tween 20) followed by the
addition of house-raised anti-mouse cIL-4 monoclonal antibody
(1:10). After 1 h incubation at room temperature, plate was washed
3x with PBS. Subsequently, 50 ml of biotin-labelled anti-mouse
antibody (1:2500) and streptavidin conjugated horseradish perox-
idase (1:4000) were delivered sequentially with washing steps in
between. Lastly, 100 ml of substrate (12-oxo-phytodienoic acid in
citrate buffer with 0.01% H2O2) was dispensed to each well of the
plate and incubated in the dark for 30 min. The subsequent
reaction was terminated with 1 M H2SO4 and plate was read at
492 nm at an ELISA reader.
Collagen assay
The soluble collagen release in the culture media was
determined by the Sircol collagen assay (Biocolor, Carrickfergus,
UK). Absorbance was measured on a multi-well plate reader and
compared to a plot of standards prepared from purified bovine
collagen to determine total collagen contents [35].
Sulphated glycosaminoglycan assay
Sulphated glycosaminoglycan (sGAG) released into the culture
media was determined using a Blyscan glycosaminoglycan assay
kit (Biocolor, Carrickfergus, UK). Absorbance was measured on a
multi-well plate reader and compared to a plot of standards
prepared from purified chondroitin-4-sulphate (derived from
bovine trachea) [36].
Assessment of NO
Concentration of nitrite, a stable product of NO was measured
in samples taken from the culture supernatants by use of a
colorimetric assay (Promega, Mannheim, Germany) based upon
the Griess’ reagent system [37].
Assessment of PGE2
Aliquots of culture media were taken for PGE2 quantification
using a PGE2 enzyme immunoassay kit (R&D Systems, Wiesba-
den-Nordenstadt, Germany) [38].
Statistical analysis
Statistical analysis was carried out with R (version 2.10.1)
utilizing a two factorial ANOVA following a Tukey’s Honestly
Significant Difference (HSD) test for post hoc comparisons. The
Figure 1. mRNA expression of proinflammatory cytokines. IL-4
transfected (pcDNA3.1.cIL-4 and pCOX-2.cIL-4) and non-transfected
chondrocytes were seeded in alginate microspheres (A) and in CaReSH
matrixes (B). Both scaffolds were stimulated with rcIL-1b (100 ng/ml)
and rcTNFa (50 ng/ml) for 96 h. mRNA expression was quantified by
qRT-PCR. The expression of IL-1, TNF and IL-6 was downregulated in IL-4
expressing scaffolds as compared to non-transfected controls on
stimulation.
doi:10.1371/journal.pone.0025749.g001
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scaffold (Alginate/CaReSH) groups were tested for equality. The
Tukey’s HSD test was used to calculate critical values to determine
significant differences of the means within the groups at p,0.05.
Results
Analysis of pro-inflammatory cytokines
Our results show that the expression of cIL-4 driven by both
CMV and COX-2 promoters in stimulated cells suppressed
endogenous production of pro-inflammatory cytokines. As shown
in Fig. 1A–1B, qRT-PCR analysis revealed that cIL-4 was able to
suppress the expression of pro-inflammatory cytokines in both
scaffolds and that cIL-4 expressed from both promoters gave
similar inhibitory activity for endogenous expression of IL-1b,
TNFa and IL-6.
Analysis of destructive enzyme mediators
As shown in Fig. 2A–2B, expression of iNOS and COX-2 was
downregulated in conditioned chondrocytes. This indicates that
cIL-4 expressed in the conditioned cells present in both scaffolds is
capable of inhibiting the production of these (enzyme) mediators in
both scaffolds. Control experiments showed that non-transfected
chondrocytes expressed high levels of both iNOS and COX-2 only
after exogenous stimulation with canine recombinant IL-1b and
TNFa (results not shown).
Figure 2. mRNA expression of enzyme mediators. IL-4 transfected (pcDNA3.1.cIL-4 and pCOX-2.cIL-4) and non-transfected chondrocytes were
seeded in alginate microspheres (A) and in CaReSH matrixes (B). Both scaffolds were stimulated with rcIL-1b (100 ng/ml) and rcTNFa (50 ng/ml) for
96 h. mRNA expression was quantified by qRT-PCR. The expression of iNOS and COX-2 was downregulated in IL-4 expressing scaffolds as compared
to non-transfected controls on stimulation.
doi:10.1371/journal.pone.0025749.g002
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We observed that cIL-4 expressed from conditioned chondro-
cytes stimulated the production of IGF-1, IL-1ra, and IL-4
(Fig. 3A–3B) at higher levels as compared to the non-transfected
control. Furthermore, expression yields for cIL-4 were apparently
higher in cells conditioned with pcDNA3.1.cIL-4 than in those
conditioned with pCOX-2.cIL-4. Irrespective of the type of
scaffold, IGF-1 and IL-1ra were expressed at similar levels from
both constructs. A sandwich ELISA revealed that the yield of cIL-
4 protein was higher in lysates and in concentrated supernatants
from the scaffolds that contained transfected cells (Fig. 4A–4B).
Yet, basal levels of cIL-4 were also detectable in the stimulated,
non-transfected cells.
The results in Fig. 5A–5B show that conditioned chondrocytes
produced 10–20 fold more mRNA coding for COL2a1 than non-
transfected cells. In contrast, the expression of COL1a1 was
already quite high in non-transfected cells and became stimulated
only by a factor of 3 to 4 in both scaffolds with cells transfected
with cIL-4. We also show that the mRNA expression of aggrecan
was significantly higher in IL-4-transfected chondrocytes in both
scaffolds compared to non-transfected cells (Fig. 5A–5B). Further-
more, the release of total collagen and sGAG was also significantly
lower in conditioned and stimulated cells as compared to that of
the non-conditioned stimulated controls (Fig. 6A–6B).
Inhibition of NO production
As shown in Fig. 7A, nitrite levels are reduced in cells
transfected with cIL-4. This is in line with the results presented
in Fig. 2A–2B which suggest that iNOS is downregulated when
cIL-4 is expressed.
Neutralizing anti-cIL-4 antibody assay
As seen from the results shown in Fig. 7B the addition of
antibody to the media prevented the downregulation of NO.
These findings support our hypothesis that the anti-inflammatory
and regenerative activities observed with both types of scaffolds
containing conditioned cells may indeed be due to the expression
of cIL-4.
Inhibition of PGE2 production
Finally, we show that cIL-4 downregulated PGE2 production
from the conditioned chondrocytes. The data shown in Fig. 8 are
Figure 3. mRNA expression of regulatory mediators. IL-4
transfected (pcDNA3.1.cIL-4 and pCOX-2.cIL-4) and non-transfected
chondrocytes were seeded in alginate microspheres (A) and in CaReSH
matrixes (B). Both scaffolds were stimulated with rcIL-1b (100 ng/ml)
and rcTNFa (50 ng/ml) for 96 h. mRNA expression was quantified by
qRT-PCR. The expression of IGF-1, IL-1ra and IL-4 was up-regulated in IL-
4 expressing scaffolds as compared to non-transfected controls on
stimulation.
doi:10.1371/journal.pone.0025749.g003
Figure 4. Detection of IL-4 protein. IL-4 transfected (pcDNA3.1.cIL-4
and pCOX-2.cIL-4) and non-transfected chondrocytes were seeded in
alginate microspheres and in CaReSH matrixes. Both scaffolds were
stimulated with rcIL-1b (100 ng/ml) and rcTNFa (50 ng/ml) for 96 h. Cell
lysate and culture media were used to measure IL-4 production by
sandwich ELISA. A lower IL-4 protein expression was found in cells
conditioned with pCOX-2.cIL-4 as compared to those with pcDNA3.1.-
cIL-4 in lysates (A) and culture media (B). In both constructs, the
expression was high as compared to non-transfected chondrocytes.
doi:10.1371/journal.pone.0025749.g004
IL-4 Expression in Chondrocyte-Scaffolds
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(Fig. 2A–2B), all representing parameters associated with inflam-
matory arthritis.
Discussion
Tissue engineering offers a plausible therapeutic approach to
the repair of damaged cartilage [39,40] through ACT [10,11,12].
Nevertheless, it has been shown previously that chondrocytes in
scaffolds are susceptible to inflammatory mediators [33]. This
scenario indirectly raises a question on the validity of ACT into
cartilage lesions surrounded by progressive inflammation. In order
to address this problem, we extended our previous work on the
application of inducible cIL-4 expression in a chondrocyte-based
model of inflammatory arthritis to 3D scaffolds. Our main
objective to present this study is to examine whether cIL-4
produced within such 3D-biomaterials can downregulate inflam-
matory mediators and can recoup extracellular matrix synthesis.
We believe that this is the first study to validate the use of
cytokine-therapy devoid of viral vectors in a 3D in vitro model of
inflammatory arthritis. Inflammatory arthritis triggered by IL-1b
and TNFa is widely accepted to be responsible for cartilage
degradation and production of inflammatory mediator that further
imply the central involvement of inflammation cascades in the
early stages of OA [14,15,41]. Since chondrocytes were condi-
tioned by transfection prior to generation of scaffolds, we coined a
new term for this type of approach: ACCT (autologous
conditioned cell therapy).
The data obtained prove that IL-4 is expressed at sufficient
levels to effectively downregulate inflammatory mediators in both
types of scaffolds. This indicates that both scaffolds containing
conditioned chondrocytes allow unrestricted diffusion of cytokines
in and out of the cells and through the matrix network into the
surrounding culture medium. The results clearly indicate the anti-
inflammatory activities of cIL-4. However, basal expression of
some of the cytokines in non-stimulated and non-transfected
control cells is in agreement with previous observations [42,43].
While qRT-PCR results indicate mRNA levels, the estimation of
catabolitessuchasNOandPGE2incellculturesupernatantsreflects
the extent of inhibition of the inflammatory mediators. Moreover,
since these mediators are end-products of the inflammation cascade,
their suppression denotes the lower levels of pro-inflammatory
Figure 5. mRNA expression of collagens and aggrecan. IL-4
transfected (pcDNA3.1.cIL-4 and pCOX-2.cIL-4) and non-transfected
chondrocytes were seeded in alginate microspheres (A) and in CaReSH
matrixes (B). Both scaffolds were stimulated with rcIL-1b (100 ng/ml)
and rcTNFa (50 ng/ml) for 96 h. mRNA expression was quantified by
qRT-PCR. The expression of COL1a1 was downregulated whereas that of
COL2a1 and aggrecan was up-regulated in IL-4 expressing scaffolds as
compared to non-transfected controls on stimulation.
doi:10.1371/journal.pone.0025749.g005
Figure 6. Release of total collagen and sGAG. IL-4 transfected
(pcDNA3.1.cIL-4 and pCOX-2.cIL-4) and non-transfected chondrocytes
were seeded in alginate microspheres and in CaReSH matrixes. Both
scaffolds were stimulated with rcIL-1b (100 ng/ml) and rcTNFa (50 ng/
ml) for 96 h. Supernatants were used to measure total collagen and
sGAG release by respective assays. A diminished release of both
collagen (A) and sGAG (B) was observed in the IL-4 expressing scaffolds
as compared to non-transfected chondrocytes on stimulation.
doi:10.1371/journal.pone.0025749.g006
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were observed, which emphasized the regulatory activity of cIL-4on
their respective catalyzing enzymes. NO also triggers chondrocyte
apoptosis and initiates matrix metalloproteinases (MMPs) that
degrade cartilage. As was observed previously, IL-4 has indeed
inhibitory activity on MMPs (MMP-1, -3 and -13) [26].
While the anti-inflammatory activities of IL-4 are well known,
restoration and/or enhancement of anabolic factors would form
an ideal therapy in arthritis. One of the important characteristics
of our approach is the ability of the pCOX-2.cIL-4 construct to
deliver the therapeutic gene (in this case cIL-4) only upon
stimulation with exogenous rcIL-1b and rcTNFa. As depicted in
Figs. 3 and 4, less cIL-4 is expressed from the pCOX-2.cIL-4
construct as from the pcDNA3.1.cIL-4 construct. This is because
the latter is expressed constitutively since driven from the CMV-
promoter. This results in an over-production of cIL-4, which is
not desirable because it has been reported that overexpression
of IL-4 may result in severe joint inflammation that is
characterized by synovial cell influx [44]. Thus, our approach is
unique in controlling the expression of a therapeutic gene
through the severity of inflammation as defined by the presence of
pro-inflammatory cytokines. Therefore, we examined the appli-
cability of a cytokine-responsive promoter for achieving efficacious
IL-4 therapy under arthritic conditions, while minimizing IL-4-
induced inflammatory arthritis under naive conditions [25].
At the same time, it is tempting to speculate that the expression
of IL-4 under these promoters in both matrices is exclusively due
to the presence of IL-4 cDNA in the vector constructs. In our
preliminary studies in monolayer culture (Figure S1), we have
determined that neither empty vectors (pcDNA3.1 and pCOX-2)
nor transfection have any influence on the inhibition of above
listed inflammatory mediators.
In line with our previous results, IL-4 has shown up-regulation
of IGF-1 and IL-1ra. In addition, reports indicate that NO
decreases IGF receptor tyrosine phosphorylation and hence
decreases IGF-1 activity [45]. IGF-1 is known for its collagen
matrix synthesis and for its anti-apoptotic functions. Stimulation of
IL-1ra additionally has anti-inflammatory activities in that it
antagonizes IL-1b. Thus, our observation that IL-4 up-regulates
IL-1ra is in agreement with previous reports [46].
Another important observation in this study is the up-regulation
of COL2a1, a matrix synthesizing protein specific for articular
cartilage. Our results in Fig. 5 denote that IL-4 produced within a
scaffold triggers the production of COL2a1, which is in line with a
previous report for chondrocyte cultures [47]. Although COL1a1
also increases to some extent after constitutive expression of IL-4
from pcDNA.IL-4, the elevated ratios between COL2a1/COL1a1
in transfected chondrocytes indicate that IL-4 may contribute to
stabilizing the re-differentiated state of chondrocytes present in the
two scaffolds (Table 2). The biochemical assessment of the levels of
collagen and sGAG, however, shows that IL-4 has an anabolic net
effect on chondrocytes because the cIL-4-transfected chondrocytes
Figure 7. Determination of NO production. IL-4 transfected
(pcDNA3.1.cIL-4 and pCOX-2.cIL-4) and non-transfected chondrocytes
were seeded in alginate microspheres and in CaReSH matrixes. Both
scaffolds were stimulated with rcIL-1b (100 ng/ml) and rcTNFa (50 ng/
ml) for 96 h. Culture media were used to measure NO levels by using
Griess’ reagent system. There was a reduced NO production in IL-4
expressing scaffolds (A). However, there was no reduction in the NO
production when the neutralizing anti-cIL-4 antibody was added in the
culture media from both scaffolds (B).
doi:10.1371/journal.pone.0025749.g007
Figure 8. PGE2 determination. IL-4 transfected (pcDNA3.1.cIL-4 and
pCOX-2.cIL-4) and non-transfected chondrocytes were seeded in
alginate microspheres and in CaReSH matrixes. Both scaffolds were
stimulated with rcIL-1b (100 ng/ml) and rcTNFa (50 ng/ml) for 96 h.
Culture media were used to measure PGE2 levels by using PGE2 enzyme
immunoassay kit. A diminished production of PGE2 was observed in IL-4
expressing scaffolds as compared to non-transfected.
doi:10.1371/journal.pone.0025749.g008
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ably due to the inhibited expression of MMPs [48,49]. Although
unlikely, the diminished release of sGAG in cell culture media may
also be a consequence of decreased sGAG production or its
retention in the scaffolds. To circumvent this issue and to
substantiate our data, we measured the mRNA expression of
aggrecan. Our results show that the expression of aggrecan is
significantly increased in both scaffolds transfected with cIL-4
under both promoters (Fig. 5A–5B). We also made efforts to
determine the expression of collagen type II at the protein level
after 96 h of stimulation but it was not detectable by both
immunocytochemistry and Western blot. We attribute this
observation to the low numbers of cells present in the scaffolds,
the detection limits of the assays and the relatively short incubation
period. Currently, we present data at the mRNA level to monitor
the expression of several marker genes for inflammatory arthritis
and cartilage. Although it has been widely accepted that cytokine
quantification in culture media is hard to determine, we attempted
to quantify IL-4 protein in the cell lysate and in concentrated
culture medium from transfected and non-transfected cells. It was
shown, compared to non-transfected cells higher concentrations of
IL-4 protein were detected in cell lysates and culture media from
conditioned cells present in both types of 3D-cultures. However,
the protein concentration was lower than that of monolayer
cultures (not shown), most probably due to limited number of cells
present in the scaffolds.
Using neutralizing anti-IL-4 antibody, we observed that
addition of this antibody to the culture media prevented the
downregulation of NO-synthesis by the conditioned cells present
in the scaffolds. Apparently the secreted cIL-4 is captured by the
antibody and hence is unable to act in a paracrine fashion which
would otherwise lead to the interference with the inflammatory
cascade eventually causing the observed drop in NO-production
(compare Fig. 7A) [50]. These findings indicate that the anti-
inflammatory and regenerative effects seen are directly related to
IL-4 produced by the conditioned chondrocytes.
Overall, our study provides evidence that IL-4 produced by cells
entrapped in a 3D scaffold such as alginate microspheres or a
CaReSH-matrix can trigger both anabolic mediators and struc-
tural elements making this cytokine an ideal therapeutic candidate
for use in 3D scaffolds utilized in transplantation.
This study directly compares both scaffolds and it appears that
both alginate and CaReSH show reproducible results. We surmise
that each of the scaffolds has its own advantage with alginate being
easy to use and suitable for the repair of small cartilage defects but
fragile during surgery. The other limitation of alginate may lie in
potentially low rates of mass transport through the alginate matrix
governed by diffusion. On the other hand, CaReSH matrices may
be quite useful to cover larger cartilage lesions than alginate and
are easy to handle as well. However, they would be more
expensive. Future experiments using animal models as well as
clinical trials will have to be performed in order to assess the
practical applicability of ACCT. Ideally if the cytokine-responsive
matrices described above do work in the patient as they do in vitro,
a promising strategy for the treatment of OA may emerge in the
future. While the data form in vitro experiments reported in this
publication are promising in many respects, it is realized that
future therapy trials will have to reveal, whether ACCT with
scaffolds containing conditioned cells will satisfy expectations as an
effective approach towards OA therapy.
Supporting Information
Figure S1 Role of transfection and/or stimulation on the
expression profile of selected markers of inflammatory arthritis.
Chondrocytes in monolayer culture were treated just with
transfection reagents (non-transfected) or mock transfected using
empty pcDNA3.1 and pCOX-2 vectors under both stimulatory
and non-stimulatory conditions. It was shown that there were only
basal levels of expression of IL-1b, IL-6, iNOS and COX-2 in
non-transfected, mock transfected and pcDNA.IL4 and pCOX-2-
IL4 transfected cells without stimulation with rcIL-1b and
rcTNFa. In contrast, on stimulation with rcIL-1b (100 ng/ml)
and rcTNFa (50 ng/ml) for 96 h, only pcDNA.IL4 and pCOX-2-
IL4 transfected cells were able to show a down-regulation of
markers of inflammatory arthritis compared to non-transfected
and mock transfected cell. This clearly indicate that the down-
regulation of markers of inflammatory arthritis was exclusively due
to IL-4 expression from the IL-4 containing constructs.
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